Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Urges Investors Suffering Losses Greater Than $100,000 In AstraZeneca To Contact Him Directly To Discuss Their Options

If you suffer losses in excess of $100,000 in AstraZeneca (NASDAQ:) between February 23, 2022 and December 17, 2024 and want to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson direct on 877-247-4292 or 212-983-9330 (Ext. 1310).

(You can also click here for more information)

New York, New York–(Newsfile Corp. – January 9, 2025) – Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AstraZeneca PLC (LON 🙂 (“AstraZeneca” or the “Company”) (NASDAQ: AZN) and reminds investors of February 21, 2025 deadline to seek the role of lead plaintiff in a federal securities class action filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that (1) AstraZeneca engaged in insurance fraud in China; (2) as a result, AstraZeneca faced high legal exposure in China, which eventually resulted in the AstraZeneca China President being detained by Chinese law enforcement authorities; (3) as a result, AstraZeneca reduced its legal risks; (4) the former, once disclosed, could harm AstraZeneca’s business activities in China; and (5) as a result, the defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or without a reasonable basis at all relevant times.

On October 30, 2024, AstraZeneca announced that Leon Wang, Executive Vice President International and President of AstraZeneca China, “is cooperating with the ongoing investigation by the Chinese authorities.”

On this news, AstraZeneca American Depositary Shares (“ADS”) fell 3.1% on October 30, 2024.

Then, on November 5, 2024, Yicai Global published an article titled “AstraZeneca Insurance Fraud Involves Dozens of Senior Executives in China, Source Says.” This article states that “(d)ozens of senior executives at AstraZeneca China were implicated in an ongoing insurance fraud case last week, according to a person familiar with the matter.” In addition, it said that “(o) the past three years, cases of insurance fraud involving AstraZeneca have emerged in Shenzhen as well as in the provinces of Fujian and Jiangxi. pharmaceutical sector for many years, pointed out by someone familiar with the matter.”

On this news, AstraZeneca ADS fell by a further 7.2% on November 5, 2024.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is substantially and generally among the class members managing and managing the litigation on behalf of the purported class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain a non-class member. Your ability to share in any recovery is not affected by the decision to serve as lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information about AstraZeneca’s conduct to contact the company, including whistleblowers, former employees, shareholders and others.

Follow us for updates on LinkedIn, on X, or on Facebook (NASDAQ:).

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Past results do not guarantee or predict similar results with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated confidentially.

To view the original version of this press release, please visit https://www.newsfilecorp.com/release/236494